PFE · 8-K · 20260804PR000094

Income Tax Rate Changes

PFIZER INC · 2026-08-04 · Importance 45 · Surprise 64

Pfizer’s reported effective tax rate on continuing operations increased to 62.4% in the second quarter of 2026 from 4.6% in the prior-year quarter. The second-quarter rate reflected a tax benefit on the pretax loss caused by changes in the jurisdictional mix of earnings, primarily associated with intangible asset impairments. For the first six months, the reported effective tax rate was 2.1%, compared with a benefit rate of negative 0.8% in 2025. The year-to-date increase primarily reflected jurisdictional earnings mix changes and the absence of favorable global income tax resolutions recorded in 2025.

Key facts

• Effective tax rate on Reported income/(loss) for Q2 2026: 62.4% source
• Effective tax rate on Adjusted income for Q2 2026: 14.1% source
• Our effective tax rates for GAAP Reported income/(loss) from continuing operations were 62.4% and 2.1% for the three and six months ended June 28, 2026, respectively source
• Our effective tax rates for GAAP Reported income/(loss) from continuing operations were 4.6% and (0.8)% for the three and six months ended June 29, 2025, respectively source
• Our effective tax rates for non-GAAP Adjusted income were 14.1% and 15.5% for the three and six months ended June 28, 2026, respectively source
• Our effective tax rates for non-GAAP Adjusted income were 13.2% and 10.3% for the three and six months ended June 29, 2025, respectively source